Fulcrum Therapeutics’ Board Grants CEO a Zero‑Price Option: Insider Confidence Signals Long‑Term Value Alignment
Insider option grant at Fulcrum Therapeutics signals executive confidence, aligning leadership with shareholder value while highlighting potential upside as the biotech’s pipeline advances.
3 minutes to read